Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Contract liabilities by Quarter
Contract liabilities — Annual reimbursement cap contracts for CF medicines in ex-U.S. government markets ($M) ($M)
Vertex Pharmaceuticals Contract liabilities: $157M in Q2 2026, up 6.9% from a year earlier.
Where the Q2 2026 figure comes from
“We had contract liabilities of $ 157.0 million and $ 171.8 million as of June 30, 2026 and December 31, 2025 , respectively, primarily related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive for our CF products.”
Source: Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Revenue Note (Contract Liabilities under International Annual Cap Contracts).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Vertex Pharmaceuticals Contract liabilities ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/intl-cf-cap-contract-liab
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.